Is West Pharmaceutical Services (WST) Undervalued Or Already Fully Valued?

Simply Wall St.09-03 03:29

West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at $338.65 on 31 August 2026. The company’s returns over the past year and past 3...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2664841112?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2026-09-03 03:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664841112","market":"nz","top_or_hot":-1,"title":"Is West Pharmaceutical Services (WST) Undervalued Or Already Fully Valued?","media":"Simply Wall St.","content":"<div>\n<p>West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at $338.65 on 31 August 2026. The company’s returns over the past year and past 3...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/is-west-pharmaceutical-services-wst-undervalued-or-already-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is West Pharmaceutical Services (WST) Undervalued Or Already Fully Valued?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs West Pharmaceutical Services (WST) Undervalued Or Already Fully Valued?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-03 03:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/is-west-pharmaceutical-services-wst-undervalued-or-already-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at $338.65 on 31 August 2026. The company’s returns over the past year and past 3...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/is-west-pharmaceutical-services-wst-undervalued-or-already-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/is-west-pharmaceutical-services-wst-undervalued-or-already-f","article_id":"2664841112","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/is-west-pharmaceutical-services-wst-undervalued-or-already-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2664841112","pubTimestamp":1788377395,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at $338.65 on 31 August 2026. The company’s returns over the past year and past 3 months add further context.\nOver the past year, West Pharmaceutical Services has combined strong upward momentum with recent softness, with a 1 year total shareholder return of 39.37% alongside a 7 day share price return that is down 2.82% and a 90 day share price return of 7.06%, which points...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","WST":"West Pharmaceutical Services Inc","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4121":"生命科学工具和服务","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","BK4567":"ESG概念","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4504":"桥水持仓","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","BK4588":"碎股"},"translate_title":"West Pharmaceutical Services (WST) 是被低估还是已经被充分估值？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WST":1.5},"content_text":"West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at $338.65 on 31 August 2026. The company’s returns over the past year and past 3 months add further context. Over the past year, West Pharmaceutical Services has combined strong upward momentum with recent softness, with a 1 year total shareholder return of 39.37% alongside a 7 day share price return that is down 2.82% and a 90 day share price return of 7.06%, which points to momentum easing rather than accelerating. Scan beyond West Pharmaceutical Services and evaluate hand-picked healthcare peers with resilient balance sheets using the list of solid balance sheet and fundamentals (53 results) as a starting point for your next idea. After a strong 1 year run and a recent dip, West Pharmaceutical Services now sits in more of a holding pattern. Does it make more sense to start a position at US$338.65 or wait for a cheaper entry based on the valuation? AdvertisementMost Popular Narrative: 16.2% Undervalued West Pharmaceutical Services is trading at $338.65 compared with a most followed fair value narrative of about $404, which frames the recent consolidation in a different light.  The analysts have a consensus price target of $403.93 for West Pharmaceutical Services based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the more bullish reporting a price target of $459.0, and the most bearish reporting a price target of just $340.0.  Read the complete narrative. Read the complete narrative. Want to understand why this fair value sits well above today’s price? The narrative focuses on sustained earnings growth, firmer margins and a premium profit multiple that is ahead of sector benchmarks. Curious which specific revenue mix shifts and margin assumptions carry the most weight in that model, and how they translate into the projected earnings base that underpins the $404 figure? Result: Fair Value of $404 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the West Pharmaceutical Services narrative still faces real pressure points, including possible demand shifts in high value components and margin strain from tariffs or pricing. Find out about the key risks to this West Pharmaceutical Services narrative. Another View On West Pharmaceutical Services Valuation While the analyst narrative frames West Pharmaceutical Services as 16.2% undervalued against a fair value of about $404, the SWS fair ratio points in a different direction. At about 42.2x P/E versus a fair ratio of 23.4x and peer and global Life Sciences averages of 39.7x and 37.6x, the stock looks expensive. Which signal should drive your next move? See what the numbers say about this price — find out in our valuation breakdown. NYSE:WST P/E Ratio as at Sep 2026Next Steps With all of this in mind, sentiment on West Pharmaceutical Services is mixed rather than one sided. It may be useful to review the details quickly and form your own view using the 2 key rewards. Looking for more investment ideas beyond West Pharmaceutical Services? If West Pharmaceutical Services has caught your attention, do not stop there. Use fresh ideas from different stock lists to pressure test your portfolio thinking.  Target resilience by reviewing companies with sturdy financial foundations through the list of solid balance sheet and fundamentals (53 results) that can help anchor your watchlist. Hunt for potential mispriced opportunities by scanning the 50 high quality undervalued stocks before other investors focus on them. Strengthen your income stream by assessing the 12 dividend fortresses that may complement growth focused positions.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if West Pharmaceutical Services might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664841112","isCrawlerRequest":true}